4D Molecular Therapeutics Inc
FDMT
Company Profile
Business description
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
Contact
5858 Horton Street
Suite 455
EmeryvilleCA94608
USAT: +1 510 505-2680
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
227
Stocks News & Analysis
stocks
Chart of the Week: Aussie dividend yields are less attractive than alternatives
The latest insights from our equity research team.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,875.70 | 1.50 | 0.02% |
| CAC 40 | 8,098.71 | 12.66 | 0.16% |
| DAX 40 | 24,023.43 | 62.84 | 0.26% |
| Dow JONES (US) | 47,885.97 | 228.29 | -0.47% |
| FTSE 100 | 9,773.99 | 0.33 | -0.00% |
| HKSE | 25,498.13 | 29.35 | 0.12% |
| NASDAQ | 22,693.32 | 418.14 | -1.81% |
| Nikkei 225 | 49,001.50 | 510.78 | -1.03% |
| NZX 50 Index | 13,256.77 | 39.14 | -0.29% |
| S&P 500 | 6,721.43 | 78.83 | -1.16% |
| S&P/ASX 200 | 8,588.20 | 3.00 | 0.03% |
| SSE Composite Index | 3,876.37 | 6.09 | 0.16% |